Challenging mucosal immunity with bacterial extracts to prevent respiratory infections: An old therapy revisited

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 61, Issue 1, 2004, Pages 4-5

  Lusuardi, M ^a  

^a PATHOLOGY UNIT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LYSATE; IMMUNOSTIMULATING AGENT; VACCINE;

ALCOHOL CONSUMPTION; ALLERGIC DISEASE; BACTERIUM; BEHAVIOR MODIFICATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM DISEASE; DISEASE EXACERBATION; DRUG MECHANISM; EDITORIAL; ENVIRONMENTAL FACTOR; EXPERIMENTAL DESIGN; HUMAN; IMMUNOSTIMULATION; INFLUENZA; LYMPHOCYTE DIFFERENTIATION; MEDICAL LITERATURE; NONHUMAN; PATIENT COMPLIANCE; PROVOCATION TEST; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; SMOKING; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

EID: 4444368416     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. World Health Organization. Acute respiratory infections: the forgotten pandemic. Bull World Health Organ 1998; 76: 101-103.
2. Murray CJ, Lopez AD. Alternative projection of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
3. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Institutes of Health, National Heart, Lung, and Blood Institute; publication no. 2701, April 2001.
4. Reid DD. Environmental factors in respiratory disease. Lancet 1958 Jun 21; 1 (7034): 1289-1294.
5. Pozzi E, Serra C. Randomized, double blind, parallel group comparison of the safety and efficacy of Lantigen B and placebo in the prevention of bacterial complication in adults with chronic respiratory diseases and children with recurrent respiratory infections. Monaldi Arch Chest Dis 2004; 61: 1, 19-27.
6. Lusuardi M, Capelli A, Carli S, Spada EL, Spinazzi A, Donner CF. Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. Chest 1993; 103 (6): 1783-91.
7. Lusuardi M, Capelli A, Donner CF. Lung immune defences after stimulation of gut-associated lymphoid tissue with OM-85 BV: a double blind study in patients with chronic bronchitis. Eur Respir Rev 1996; 6 (36): 182-185.
8. Bowman LM, Holt PG. Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract. Infect Immun 2001 Jun; 69 (6): 3719-3727.
9. Orcel B, Delclaux B, Baud M, Derenne JP. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 1994 Mar; 7 (3): 446-452.
10. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARIIS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997; 156 (6): 1719-1724.
11. Schaad UB, Mutterlein R, Goffin H; BV-Child Study Group. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest 2002; 122 (6): 2042-2049.
12. Bergemann R, Brandt A, Zoellner U, Donner CF. Preventive treatment of chronic bronchitis: a meta-analysis of clinical trials with a bacterial extract (OM-85 BV) and a cost-effectiveness analysis. Monaldi Arch Chest Dis 1994, 49: 4, 302-307.
13. Profeta ML, Guidi G, Meroni PL, Palmieri R, Palladino G, Cantone V, Zanussi C. Influenza vaccination with adjuvant RU41740 in the elderly. Lancet 1987; i: 973.